SLC22A1 and type 2 diabetes mellitus: Most studies evaluating the effects of SLC22A1 gene polymorphisms on the therapeutic response to metformin in patients with type 2 diabetes (T2D) have focused on European, Asian, and Caucasian populations (12–14).